homeWelcome, sign in or click here to subscribe.login
     


 

 

Business


print  email to a friend  reprints add to mydjc  

February 2, 2012

Dendreon

Dendreon Corp.'s board of directors elected John Johnson as president and chief executive officer. Johnson will succeed Mitchell Gold, who has served as president and CEO for nearly a decade. Gold is now executive chairman and will serve until June 30, when he will continue to serve as a director and Johnson will become chairman. Johnson has been a member of Dendreon's board since August of 2011. He has 30 years of experience in the life sciences industry and was president, CEO and director at Savient Pharmaceuticals and president of Eli Lilly's Oncology Business Unit.




Email or user name:
Password:
 
Forgot password? Click here.